Search Results

The Celsite® System is recommended for use whenever patient therapy requires repeated I.V. Access for injection, drug therapy and/or blood sampling.

Not Found

This document is a 510(k) clearance letter from the FDA for a medical device called the "Celsite® Dual Venous Access System." It states that the device is substantially equivalent to legally marketed predicate devices, allowing it to be marketed.

Key information:

• Acceptance Criteria and Device Performance: The document does not contain acceptance criteria or study results demonstrating device performance against such criteria. It's an approval letter based on "substantial equivalence" to a predicate device, not a performance study report.
• Study Details (Sample Size, Provenance, Experts, Adjudication, MRMC, Standalone, Ground Truth, Training Set): As this is an FDA clearance letter based on substantial equivalence, rather than a clinical trial or performance study report, none of this information is available within the provided text. The FDA determines substantial equivalence based on a comparison to predicate devices regarding indications for use, technological characteristics, and safety and effectiveness information, but the specific performance data against quantified acceptance criteria and the detailed study design elements you've asked for are typically found in the 510(k) submission itself, not the clearance letter.

Therefore, for this specific input, I must state that the requested information regarding acceptance criteria, device performance, and study details is not provided in the given FDA clearance letter.

Ask a specific question about this device